Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

• DOI: 10.6004/jnccn.2022.0062
• Publication Date: 2022-12-01
• Authors: Amar Gajjar; Anita Mahajan; Mohamed S Abdelbaki; Clarke Anderson; Reuben Antony; Tejus Bale; Ranjit S. Bindra; Daniel C. Bowers; Kenneth J. Cohen; Bonnie Cole; Kathleen Dorris; Ralph Ermoian; Andrea Franson; Jeffrey Helgager; Daniel Landi; Chi Lin; Laura Metrock; Ronica H. Nanda; Joshua D. Palmer; Sonia Partap; Ashley Plant; Sumit Pruthi; Renée M. Reynolds; Paul Ruggieri; Duncan Stearns; Phillip Storm; Anthony Wang; Katherine N Warren; Nicholas Whipple; Wafik Zaky; Nicole R. McMillian; Lenora A. Pluchino
• Keywords: Pediatric cancer

Central nervous system (CNS) cancers account for approximately one quarter of all pediatric tumors and are the leading cause cancer-related death in children. More than 4,000 brain CNS diagnosed each year children teens, incidence rate has remained stagnant recent years. The most common malignant gliomas, embryonal consisting predominately medulloblastomas, germ cell tumors. inaugural version NCCN Guidelines Pediatric Nervous System Cancers focuses on diagnosis management patients with diffuse high-grade gliomas. information contained is designed to help clinicians navigate complex prognosis these highly aggressive generally poor, 5-year survival rates <20% despite use combined modality therapies surgery, radiation therapy systemic therapy. Recent advances molecular profiling expanded targeted whose harbor certain alterations. However, enrollment a clinical trial preferred treatment eligible patients.